The Discovery of CB2 — The Immune System's Cannabinoid Receptor

Cloning from Cancer Cells

Sean Munro was not a cannabinoid researcher. He was a cell biologist whose primary interest was the Golgi apparatus — the cellular machinery that processes and sorts proteins. He had been a group leader at the MRC-LMB since 1989. But in the early 1990s, the rush to clone G-protein-coupled receptors was drawing labs from across molecular biology into receptor hunting, and Munro's team had the tools.

They started with HL-60 cells — a human promyelocytic leukemia cell line widely used in immunology research. These cells can be chemically differentiated into granulocyte-like immune cells, making them a rich source of immune-relevant receptor genes.

The tissue distribution was the surprise. This wasn't another brain receptor. CB2 was in the immune system — spleen, tonsils, white blood cells. Cell sorting pinpointed the signal to monocytes and macrophages. The paper called it "a peripheral receptor for cannabinoids," and the label stuck for decades.

360 Amino Acids, 44% Identity

The paper was published September 2, 1993, in Nature — the same journal that had published CB1's cloning three years earlier. Five pages. Three authors from one of the most storied laboratories in science.

What Munro, Thomas, and Abu-Shaar had found:

• A G-protein-coupled receptor, 360 amino acids, seven transmembrane domains
• Gi/o-coupled, inhibits adenylate cyclase — same signaling family as CB1
• Only 44% amino acid identity with CB1 (cross-species CB2 homology is ~80%, compared to CB1's 97-99%)
• Two human isoforms: one predominantly in testis, the other mainly in spleen
• Gene designated CNR2, GenBank accession X74328

The endocannabinoid system now had two receptors. But they were not equals. CB1 got the attention — it was in the brain, it mediated the high, it was the target for drug development. CB2 was "peripheral." Immune. Unglamorous.

That would change.

The Sibling Receptors

Both receptors are GPCRs. Both couple to Gi/o proteins. Both bind THC and the endocannabinoids anandamide and 2-AG. But their distribution and function are fundamentally different — which is exactly what makes CB2 therapeutically interesting. If you could activate CB2 without touching CB1, you might get the anti-inflammatory and analgesic effects of cannabinoids without the psychoactive effects. Pain relief without the high.

That idea has driven two decades of drug development. The results have been... complicated.

The Identity Crisis

The 1993 characterization was clean: CB2 in immune cells, not in brain. But science rarely stays that simple.

The "identity crisis" — as a landmark 2010 review called it — matters because it determines CB2's therapeutic scope. If CB2 is only on immune cells, it's a target for peripheral inflammation and pain. If it's also on brain cells during disease states, it could be a target for Alzheimer's, Parkinson's, stroke, and traumatic brain injury — conditions where neuroinflammation drives damage.

Not Just Peripheral

The brain mapping that has emerged since 1993 tells a more complex story than the original paper suggested.

The critical insight: CB2 is an inducible receptor in the brain. In a healthy brain, it's essentially absent. During neuroinflammation — a stroke, a traumatic injury, Alzheimer's progression — microglia activate and CB2 expression surges. This makes it a potential therapeutic target specifically for disease states, not for baseline brain function. An elegant biological design: a receptor that appears when and where it's needed.

The Most Promising Target That Hasn't Worked Yet

The therapeutic logic for CB2 drugs is irresistible: activate CB2 to reduce pain and inflammation without any psychoactive effects. No high, no cognitive impairment, no abuse potential. Decades of preclinical research have validated this concept — in animals.

The preclinical results are genuinely impressive. CB2 agonists reduce inflammation in arthritis models, provide analgesia in neuropathic pain models, show neuroprotection in Alzheimer's and stroke models, reduce fibrosis in liver disease, and slow tumor growth in some cancer models. The data in animals is as good as any target in pharmacology.

But none of it has translated to humans.

The failures likely stem from a convergence of problems: species differences in CB2 expression patterns between rodents and humans, the difficulty of reliably detecting CB2 protein in human tissues (antibody specificity remains a major challenge), and the possibility that CB2's role in human physiology differs from its role in mice in ways we don't yet understand.

Where CB2 Research Stands Now

CB2 remains an active area of research — arguably more active now than at any point since its discovery. Current work focuses on:

• Neuroinflammation: CB2 activation on microglia as a target for neurodegenerative diseases
• Better tools: Developing reliable antibodies and imaging agents for CB2 detection in human tissue
• Allosteric modulators: Drugs that fine-tune CB2 rather than fully activating it
• Peripherally-restricted agonists: Ensuring CB2 drugs stay out of the brain (ironic, given that brain CB2 might be therapeutically useful)
• Combination approaches: Using CB2 activation alongside other anti-inflammatory strategies

The endocannabinoid system that CB2 helped define is now recognized as one of the most important regulatory networks in human physiology. CB2's specific contribution — the immune and inflammatory arm of that system — may yet yield the therapeutic breakthroughs its discovery promised. But the gap between preclinical promise and clinical reality remains one of the defining frustrations of cannabinoid pharmacology.

Myth vs. Reality

✕Myth

CB2 is only found in the immune system and has nothing to do with the brain.

✓Reality

CB2 was originally described as a 'peripheral receptor' absent from the brain. Three decades of subsequent research have shown that CB2 is expressed in brain microglia during neuroinflammation and possibly in some neurons. It's not a brain receptor the way CB1 is, but it's not absent from the brain either.

The Evidence

Van Sickle et al. (2005) demonstrated CB2 in brainstem neurons. Multiple groups have shown CB2 upregulation on activated microglia in Alzheimer's, stroke, and TBI models. The 'identity crisis' review (Atwood & Mackie, 2010) documents the evolving understanding. However, some positive findings have failed to replicate in CB2 knockout control tissue, so the exact extent of neuronal expression remains debated.

Atwood & Mackie (2010), PMC2931549; Van Sickle et al. (2005), Nature

Frequently Asked Questions

What is the CB2 receptor and how is it different from CB1?

CB2 is the second cannabinoid receptor, found primarily in immune cells (spleen, white blood cells, macrophages) rather than in the brain. It shares only 44% of its amino acid sequence with CB1. While CB1 mediates the psychoactive effects of THC — the high — CB2 activation is non-psychoactive and primarily modulates immune and inflammatory responses. Both receptors are part of the endocannabinoid system and both respond to THC and the body's own endocannabinoids, but they serve fundamentally different physiological roles.

Could CB2 drugs treat pain without getting you high?

That's been the hope for thirty years. Because CB2 is primarily on immune cells rather than brain neurons, drugs that selectively activate CB2 should reduce inflammation and pain without psychoactive effects. Preclinical studies in animals have been very promising — CB2 agonists work in models of arthritis, neuropathic pain, and neuroinflammation. However, no CB2-targeted drug has succeeded in human clinical trials to date. Species differences in CB2 expression, difficulty detecting the receptor reliably in human tissues, and poor translation from animal models to human biology are the likely reasons.